EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Oxford Nanopore Technologies EBITDA Margin % Related Terms
Oxford Nanopore Technologies EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:ONT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Oxford Nanopore Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford Nanopore Technologies EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford Nanopore Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Oxford Nanopore Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford Nanopore Technologies (LSE:ONT) has a EBITDA Margin % of -36.09% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxford Nanopore Technologies and its competitors. According to the industry distribution chart, Oxford Nanopore Technologies ranks #427 out of 945 companies in the Biotechnology industry, placing it in the top 45.2%.
Is Oxford Nanopore Technologies' EBITDA Margin % too high?
Oxford Nanopore Technologies' current EBITDA Margin % is -36.09%. Based on the distribution chart, Oxford Nanopore Technologies ranks #427 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oxford Nanopore Technologies has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oxford Nanopore Technologies' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oxford Nanopore Technologies ranks #427 out of 945 companies for EBITDA Margin %. This puts Oxford Nanopore Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Oxford Nanopore Technologies and its competitors. Oxford Nanopore Technologies's current EBITDA Margin % is -36.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford Nanopore Technologies stock overvalued right now?
Based on GuruFocus' analysis, Oxford Nanopore Technologies (LSE:ONT) is currently considered Significantly Undervalued. The stock's GF Value™ is £1.87, compared to a current price of £1.15 — trading 38.7% below its estimated fair value. The current EBITDA Margin % is -36.09%. Oxford Nanopore Technologies' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Oxford Nanopore Technologies (LSE:ONT), the current EBITDA Margin % is -36.09% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford Nanopore Technologies (LSE:ONT) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford Nanopore Technologies stock appears to be undervalued.
The current stock price of £1.15 is trading 38.7% below its estimated GF Value™ of £1.87.
GuruFocus considers Oxford Nanopore Technologies to be Significantly Undervalued.
Key valuation signals for LSE:ONT:
EBITDA Margin %: -36.09%
GF Value™: £1.87 vs. price of £1.15 (38.7% below fair value)
No single metric tells the full story. See the LSE:ONT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford Nanopore Technologies PLC is involved in researching, developing, manufacturing and commercializing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that provides rich data, is fast, accessible and easy to use, and which allows the real-time analysis of DNA or RNA. It has developed and brought to market a new generation molecular sensing platform based on nanopores. The first application is DNA/RNA sequencing and the platform is also being developed for the analysis of proteins and metabolites. It operates in single segment of providing products and services related to the sale and use of its nanopore-based sensing technology. Geographically its operations are spread across EMES, AMR, and APAC.
74GF Score
Get the complete analysis for LSE:ONT
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:ONT has been successfully added to your 
